FDA plans ultra-fast review of three psychedelic drugs following Trump directive

WASHINGTON (AP) — The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach. P...

Redirecting to full article...